Vyne Therapeutics publishes investor presentation on Yarrow Bioscience, YB-101 anti-TSHR program for Graves' disease, thyroid eye disease

VYNE Therapeutics Inc

VYNE Therapeutics Inc

VYNE

0.00
  • Vyne investor deck outlined a planned reverse merger with Yarrow Bioscience, with a Q3 2026 expected close.
  • Combined company expected to trade on NASDAQ under ticker YARW.
  • Yarrow’s lead program YB-101, an anti-TSHR antibody for Graves’ disease and thyroid eye disease, set to start a Phase 2a/2b trial in Q2 2026.
  • Phase 2a proof-of-concept data in Graves’ disease targeted for 2H 2027; Phase 2b portion planned to begin in H1 2028.
  • $200 million raised to date, including an expected $100 million pre-closing financing; cash runway projected into 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyne Therapeutics Inc. published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.